Evidence map›Paper›PMID 38037319›Full record

ReviewCancer research and treatment2024

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP.

Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo and 27 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Miso KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Hyo Sup ShimDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Sheehyun KimDepartment of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
In Hee LeeDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Jihun KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shinkyo YoonDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hyung-Don KimDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Inkeun ParkDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jae Ho JeongDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Changhoon YooDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jaekyung CheonDepartment of Oncology,Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
In-Ho KimDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jieun LeeDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sook Hee HongDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sehhoon ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hyun Ae JungDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jin Won KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Han Jo KimDivision of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
Yongjun ChaDivision of Medical Oncology, Center for Colorectal Cancer, National Cancer Center, Goyang, Korea.
Sun Min LimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Han Sang KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Choong-Kun LeeDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jee Hung KimDivision of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Sang Hoon ChunDivision of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jina YunDivision of Hematology/Oncology, Department of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
So Yeon ParkDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Hye Seung LeeDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Yong Mee ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Soo Jeong NamDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kiyong NaDepartment of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
Sun Och YoonDepartment of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ahwon LeeDepartment of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kee-Taek JangDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hongseok YunDepartment of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Sungyoung LeeDepartment of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Jee Hyun KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Wan-Seop KimDepartment of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

Funding

Ministry of Health and Welfare HA22C0052National Cancer Center
6 · The paper itself

Abstract

In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Indexed as

High-Throughput Nucleotide SequencingNeoplasmsBiomarkers, TumorCirculating Tumor DNAGenetic TestingHumansPractice Guidelines as TopicBiomarkers, TumorCirculating Tumor DNAKoreaNext-generation sequencingPrecision medicineSolid cancer

Identifiers

PMID38037319
PMCPMC11261187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.